Shuttle Pharmaceuticals (NASDAQ:SHPH) Upgraded at Wall Street Zen

Shuttle Pharmaceuticals (NASDAQ:SHPH) was upgraded by Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ SHPH opened at $3.65 on Friday. The stock’s 50 day moving average price is $5.69 and its two-hundred day moving average price is $10.59. Shuttle Pharmaceuticals has a 52-week low of $2.90 and a 52-week high of $55.90. The stock has a market capitalization of $2.34 million, a P/E ratio of -0.08 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other Shuttle Pharmaceuticals news, major shareholder Financial Lp Hrt bought 25,836 shares of the business’s stock in a transaction on Monday, June 29th. The shares were purchased at an average price of $3.44 per share, with a total value of $88,875.84. Following the completion of the acquisition, the insider directly owned 71,842 shares of the company’s stock, valued at approximately $247,136.48. The trade was a 56.16% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 36,550 shares of company stock worth $123,759 in the last quarter. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 3rd quarter worth approximately $357,000. Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Ikarian Capital LLC bought a new position in Shuttle Pharmaceuticals during the 4th quarter worth $124,000. 4.58% of the stock is owned by institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .